National Psoriasis Foundation Medical Board and the International Psoriasis Council
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors
Ce document comprend 1 recommandation et 1 tableau.
Contenu en anglais
Synthèse
Although testing for latent tuberculosis (TB) infection has been standard practice for psoriasis patients being treated with interleukin (IL) 17 or IL-23 inhibitors, evidence for this practice is weak.
Messages clés
Clinical data suggest that progression of latent tuberculosis infection to active disease during psoriasis treatment with interleukin-17 or interleukin-23 inhibitors is rare.